

SHORT CURRICULM VITAE

Luciana Scalone was born in Avola (Siracusa), Italy, on July 3rd, 1974.

Education: After graduating in Pharmacy in 2000, at the University of Milan (Faculty of Pharmacy), Dr Scalone specialized in Medical Statistics (University of Milan, Faculty of Medicine) in 2005 and took a doctorate in Pharmaceutical Sciences in 2008 (University of Naples Federico II, Faculty of Pharmacy). During those years, she also attended a number of other postgraduate national and International courses and seminars focusing on the areas dealt with in her research activity.

Current position: senior researcher in Health Technology Assessment and Outcomes Research at the CHARTA (Center for Health Associated Research and Technology Assessment) Foundation, based Milano, and at the Research Centre of Public Health (CESP) of the University of Milano – Bicocca, where she is head of the Outcomes Research Unit. Her main research interests include economic evaluations and outcomes research, including QoL, utility and preferences assessment using the Discrete Choice Experiments methodology, in different disease areas.

Past research position: past research was performed at the CIRFF (Centro Interdipartimentale di Ricerca in Farmacoeconomia e Farmacoutilizzazione) of the University of Naples Federico II, at the Centre of Pharmacoeconomics of University of Milano, at the Health Economics Research Unit (HERU) of the University of Aberdeen (Scotland) and at the Oasi Maria SS Hospital IRCCS (Istituto di Ricerca e Cura a Carattere Scientifico), in Troina (Enna, Italy).

Teaching experience: currently contract professor at the master (Level II) in valuation and management of the health technologies and services, at the University of Milano-Bicocca. During the past years Luciana has gained wide teaching experience as lecturer and contract professor in several undergraduate and postgraduate Italian courses/masters/schools.

Publications, editorial contributions, participation at congresses: author of more than 60 full text papers published in peer reviewed National and International journals and chapter books (see full list below), and is author of more than 100 posters and podium presentations discussed in numerous National and International congresses and meetings. From 2006, Luciana has reviewed several full papers submitted for publication in different International Scientific Journals, and from 2014 she is Associate Editor of the Health and Quality of Life Outcomes Journal.

Publications of full text papers and chapters

[1] Dell’Osso B, Marazziti D, Albert U, Pallanti S, O Gambini, Tundo A, Zanaboni C, Servello D, Rizzo R, Scalone L, Benatti B, Altamura AC, Porta M. Parsing the phenotype of obsessive-

compulsive tic disorder (OCTD): a multidisciplinary consensus. *International Journal of Psychiatry in Clinical Practice*, 2017 DOI: 10.1080/13651501.2017.1291822

[2] Gualtierotti R1, Ingegnoli F1, Scalone L2, Cortesi P2, Bruschi E3, Gerosa M4, Meroni PL4. Feasibility, acceptability and construct validity of EQ-5D in systemic sclerosis. *Swiss Med Wkly*. 2017 Jan 19;146:w14394. doi: smw.2016.14394. eCollection 2017

[3] Faggioli G1, Scalone L2, Mantovani L2, Stella A. Regarding "Exploring patient involvement in decision making for vascular procedures". [Letter to the Editor] *J Vasc Surg.*, 2016;63(6):1668

[4] Scalone L, Cortesi PA. About the Reliability of the Critical Review to Investigate the Generalizability of Economic Evaluations Conducted in Italy. (Letter to the Editor) *Value in Health*, 2016. IN PRESS

[5] Scalone L; Cortesi PA; Ciampichini R; Cesana G; Mantovani LG. Health Related Quality of Life norm data of the general population in Italy: results using the EQ-5D-3L and EQ-5D-5L instruments. *Epidemiology Biostatistics and Public Health*, 2015; 12 (3): e11457 1-15

[6] Scalone L; Fagioli S; Ciampichini R; Gardini I; Bruno R; Pasulo L; Lucà MG; Fusco F; Gaeta L; Del Prete A; Cesana G; Mantovani LG. The societal burden of chronic liver diseases: results from the COME study. *BMJ Open Gastroenterology*, 2015 Mar 30;2(1):e000025. doi: 10.1136/bmjgast-2014-000025. eCollection 2015

[7] Rocino A, Cortesi PA, Scalone L, Mantovani LG, Crea R, Gringeri A; Immune tolerance induction in patients with haemophilia a and inhibitors: effectiveness and cost analysis in an European Cohort (The ITER Study). *Haemophilia*, 2016;22(1):96-102

[8] Gualtierotti R, Ingegnoli F, Two R, Meroni PL, Khanna D, Adorni G, Becciolini A, Ciavarella T, Marfia G, Murgo A, Scalone L, Ughi N, Zeni S; VERITAS study group. Reliability and validity of the Italian version of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument in patients with systemic sclerosis. *Clin Exp Rheumatol*. 2015;33(4 Suppl 91): S55-60

[9] F Zucco, R Ciampichini, A Lavano, A Costantini, M De Rose, P Poli, G Fortini, L Demartini, E De Simone, V Menardo, P Cisotto, M Meglio, L Scalone, LG Mantovani. Cost-Effectiveness and Cost-Utility Analysis of Spinal Cord Stimulation in Patients With Failed Back Surgery Syndrome: Results From the PRECISE Study. *Neuromodulation*, 2015, 18(4):266-76

[10] L. Scalone, P.A. Cortesi. Cost-utility analysis of biologic therapies to treat chronic plaque psoriasis in asthma: the importance of using updated and adequate social tariffs to calculate QALYs. (Letter to the Editor) *Biodrugs*, 2015; 29(1):69

[11] L. Scalone, G. Cesana, G. Furneri, R. Ciampichini, P. Beck-Peccoz, V. Chiodini, S. Mangioni, E. Orsi, C. Fornari, L.G. Mantovani. Burden of Diabetes Mellitus Estimated with a Longitudinal Population-Based Study Using Administrative Databases. *PLoS One*, 2014 Dec 3;9(12):e113741

[12] P.A. Cortesi, L. Scalone, L.G. Mantovani. Cost-Effectiveness Analysis of New Drugs for Chronic Hepatitis C: The Importance of Updating Utility Values. (Letter to the Editor) *Hepatology*,

2014: Jul 12

[13] L. Scalone, P.A. Cortesi, L.G. Mantovani, A. Belisari, F. Ayala, Belloni A. Fortina, D. Bonamonte, G. Borroni, S.P. Cannavò, F. Guarneri, A. Cristaudo, O. De Pità, R. Gallo, G. Girolomoni, M. Gola, P. Lisi, P.D. Pigatto, R. Satta, A. Giannetti. Clinical epidemiology of hand eczema in Italian patients accessing dermatological reference centers. *British Journal of Dermatology*, 2014. [Epub ahead of print]

[14] L. Scalone, P.F. Stalmeier, S. Milani, P.F. Krabbe. Values for health states with different life durations. *European Journal of Health Economics*, 2014 Sep 30. [Epub ahead of print]

[15] P.A. Cortesi, L. Scalone, G. Angelini, A. Belisari, S.P. Cannavò, A. Cristaudo, O. De Pità, R. Gallo, A. Giannetti, M. Gola, P. Pigatto, L.G. Mantovani. Cost and quality of life in patients with severe chronic hand eczema refractory to standard therapy with topical potent corticosteroids. *Contact Dermatitis*, 2013; 70(3):158-68

[16] L. Scalone, P.A. Cortesi, R. Ciampichini, A. Belisari, L.S. D'Angiolella, G. Cesana, L.G. Mantovani. Italian population-based values of EQ-5D health states. *Value in Health*, 2013; 16(5):814-22

[17] L. Scalone, P.A. Cortesi, G. Spinella, B. Pane, G. Cesana, L. G. Mantovani, D. Palombo. Use of Health-Related Quality-of-Life Measurements to Estimate Individuals' Health on screening. *Acta Chirurgica Belgica*, 2013; 113(6):406-14

[18] Cortesi PA, Mencacci C, Luigi F, Pirfo E, Berto P, Sturkenboom MC, Lopes FL, Giustra MG, Mantovani LG, Scalone L. Compliance, persistence, costs and quality of life in young patients treated with antipsychotic drugs: results from the COMETA study. *BMC Psychiatry*. 2013; 13(98): 2-16

[19] Scalone L, Ciampichini R, Fagioli S, Gardini I, Fusco F, Gaeta L, Del Prete A, Cesana G, Mantovani LG. Comparing the performance of the standard EQ-5D 3L with the new version EQ-5D 5L in patients with chronic hepatic diseases. *Qual Life Res*. 2013; 22(7):1707-16

[20] Janssen MF, Pickard AS, Golicki D, Gudex C, Niewada M, Scalone L, Swinburn P, Busschbach J. Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L across eight patient groups: a multi-country study. *Qual Life Res*. 2013; 22(7):1717-27

[21] L. Scalone, L. S D'Angiolella, L.G. Mantovani. Health economics of factor VIII products. In: Factor VIII, Treatment options, Dosing and administration, Prophylaxis and pharmacokinetics. *Hospital Pharmacy Europe: Special supplement*, UK 2013

[22] Turchetti G, Scalone L, Della Casa Alberighi O, Montella S, Cortesi PA, Mantovani L.G. The rationale of pharmacoeconomic analysis in rheumatologic indications. *Clinical And Experimental Rheumatology*, 2012; 30:S64-S71

[23] Cortesi PA, Scalone L, D'Angiolella LS, Belisari A, Fusco F, Olivieri I, Mantovani L.G. Systematic literature review on economic implications and pharmacoeconomic issues of psoriatic arthritis. *Clinical And Experimental Rheumatology*, 2012; 30: S126-S131

[24] Moia M, Mantovani LG, Carpenedo M, Scalone L, Monzini MS, Cesana G, Mannucci PM.

Patient preferences and willingness to pay for different options of anticoagulant therapy. *Internal and Emergency Medicine*, 2013; 8(3):237-43

[25] van Hout B, Janssen M.F., Feng YS, Kohlmann T, Golicki D, Scalone L, van Busschbach J, Lloyd A, Kind P, Pickard A.S. Value sets for the EQ-5D-5L: A mapping approach. *Value in Health*, 2012; 15(5):708-15

[26] Scalone L, Carminati M, Bonhoeffer P, Cortesi PA, Mantovani LG, Cesana G, Hess J. Patients' and physicians' needs, experiences and preferences in the treatment of right ventricular outflow tract dysfunction. *Italian Journal of Public Health*, 2011; 9: 73-83

[27] Scalone L, Tomasetto C, Matteucci MC, Selleri P, Broccoli S, Pacelli B, Cavrini G. Assessing Quality of Life in Children and Adolescents: Development and Validation of the Italian Version of the EQ-5D-Y. *Italian Journal of Public Health*, 2011; 8 (4): 331-341

[28] Scalone L, Mantovani LG. L'impatto umanistico delle malattie: La valutazione della Qualità della Vita Associata allo Stato di Salute; Mantovani LG, Scalone L. L'impatto economico delle malattie: principi, concetti, applicazioni; Mantovani LG, Scalone L. Valutazione economica delle tecnologie sanitarie. Principi. Concetti e applicazioni; In Mantovani LG (a cura di). *Health Technology Assessment. Principi, concetti, strumenti operativi*. Il Sole24ore Libri. Milano. 2011

[29] Scalone L, Watson V, Ryan M, N Kotsopoulos, R Patel. Evaluation of preferences for Genital Herpes Treatment. *Sexually Transmitted Diseases*, 2011; 38 (9):802-807

[30] Faggioli G, Scalone L, Mantovani LG, Borghetti F, Stella A. Preferences of Patients, Their Family Caregivers and Vascular Surgeons in the Choice of Abdominal Aortic Aneurysms Treatment Options: The PREFER Study. *European Journal of Vascular and Endovascular Surgery*, 2011; 42 (1): 26-34

[31] Stolk EA, Oppe M, Scalone L, Krabbe PF. Discrete Choice Modeling for the quantification of health states: the case of the EQ-5D. *Value in Health*, 2010; 13(8): 1005-1013

[32] Wille N, Badia X, Bonsel G, Buström K, Cavrini G, Devlin N, Egmar AC, Greiner W, Gusi N, Herdman M, Jelsma J, Kind P, Scalone L, Ravens-Sieberer U. Development of the EQ-5D-Y: a child-friendly version of the EQ-5D. *Quality of Life Research*, 2010; 19(6): 875-886

[33] Ravens Sieberer U, Wille N, Badia X, Bonsel G, Buström K, Cavrini G, Devlin N, Egmar AC, Gusi N, Herdman M, Jelsma J, Kind P, Olivares PR, Scalone L, Greiner W. Feasibility, reliability, and validity of the EQ-5D-Y: results from a multinational study. *Quality of Life Research*, 2010; 19(6): 887-897

[34] Gualtierotti R, Scalone L, Ingegnoli F, Cortesi P, Lubatti C, Zeni S, Meroni PL. Health related quality of life assessment in patients with systemic sclerosis. *Reumatismo*, 2010;62(3):210-4

[35] Scalone L, Mantovani LG (editors). *Proceedings of the 25th Scientific Plenary Meeting of the EuroQol Group*. EuroQol Group. Rotterdam. 2010

[36] L Scalone, F Borghetti, G Brunori, BF Viola, B Brancati, L Sottini, LG Mantovani, G Cancarini. Cost-Benefit analysis of supplemented very low protein diet versus dialysis in elderly CKD5 patients.

Nephrology, Dialysis, Transplantation, 2010; 25: 907-913

[37] L Scalone, LG Mantovani, F Borghetti, S von Mackensen, A Gringeri. Patients', Physicians', and Pharmacists' Preferences towards Coagulation Factor Concentrates to Treat Haemophilia with Inhibitors: Results from the COHIBA Study. *Haemophilia*, 2009; 15: 473-486

[38] L Scalone, LG Mantovani, M Krol, D Rofail, S Ravera, MG Bisconte, C Borgna-Pignatti, Z Borsellino, P Cianciulli, D Gallisai, L Prossomariti, I Stefano, MD Cappellini. Costs, quality of life, treatment satisfaction and compliance in patients with β -thalassemia major undergoing iron chelation therapy: the ITHACA study. *Current Medical Research and Opinion*, 2008;24(7):1905-1917

[39] L Scalone. Investing in hemophilia care: benefits and costs for patients and society. *Seminars in Hematology*, 2008; 45: S31-S34

[40] N Baranzoni, L Scalone, LG Mantovani, S de Portu, MS Monzini, A Giannetti. Validation of The Italian Version Of The Dermatology Life Quality Index. *Giornale Italiano di Dermatologia e Venereologia*, 2007; 142(3): 209-14

[41] N Baranzoni, L Scalone, LG Mantovani, S de Portu, MS Monzini, A Giannetti. Validation of The Italian Version Of The Infants' Dermatitis Quality of Life and Family Dermatitis Impact Indexes. *Giornale Italiano di Dermatologia e Venereologia*, 2007; 142(5): 423-432

[42] L Scalone, S de Portu, LG Mantovani. *Farmacoeconomia*. Charter in eBook by C Gelmetti, untitled "La scuola dell'atopia"; Springer 2007: ISBN 8847005922, 9788847005921

[43] L Scalone, F Borghetti, Il trattamento dell'Herpes Genitale: le preferenze dei pazienti contano? *Farmacoeconomia news*, Anno XI n. 3, 2007

[44] Scalone L, Mantovani LG, Mannucci PM, Gringeri A; COCIS Study Investigators. Quality of life is associated to the orthopaedic status in haemophilic patients with inhibitors. *Haemophilia*. 2006 Mar;12(2):154-62

[45] F Rossetti, S De Portu, E Menditto, L Scalone, S Bustacchini, C Cricelli, LG Mantovani. Pharmacoeconomic Consequences of Amlodipine Besylate Therapy in Patients undergoing PTCA. *Pharmacological Research*, 2006; 53: 197-201

[46] S de Portu, E Menditto, L Scalone, S Bustacchini, C Cricelli, LG Mantovani. The Pharmacoeconomic Impact of Amlodipine use on Coronary Artery Disease. *Pharmacological Research*, 2006; 54: 158-163

[47] F Di stasi, L Scalone, S de Portu, E Menditto, LG Mantovani. Cost effectiveness analysis of bisoprolol treatment for heart failure. *Italian Heart Journal*, 2005; 6: 950-955

[48] Mantovani LG, Monzini MS, Mannucci PM, Scalone L, Villa M, Gringeri A; The Conan Study Group. Differences between patients', physicians' and pharmacists' preferences for treatment products in haemophilia: a discrete choice experiment. *Haemophilia*, 2005; 11(6): 589-97

[49] L Scalone. Conseguenze e strategie di intervento per l'Herpes Genitale. *Farmacoeconomia news*, Anno IX n. 2, 2005

- [50] L Scalone. L'analisi delle decisioni come strumento utilizzato per un efficiente impiego delle risorse sanitarie. Anno VIII n. 2, 2004: 20-24
- [51] L Scalone. Inibitori verso i fattori della coagulazione nel trattamento dell'emofilia: il costo di una malattia rara. Anno VIII n. 1, 2004: 19-23
- [52] A Gringeri, LG Mantovani, L Scalone, PM Mannucci. Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group. Blood, 2003; 102: 2358-2363
- [53] L Scalone, S de Portu, P Minghetti, LG Mantovani. Pharmaceutical Expenditure: Aspects of Cost Containment in Italy. Pharmaceutical Finance, Economics & Policy, 2003; 12 (4); 337-350
- [54] A Gringeri, L Scalone. La qualità della vita: un nuovo concetto di salute ed efficacia degli interventi terapeutici, un nuovo approccio di scelte in Sanità. La Medicina Estetica, 2003; n° 2
- [55] L Scalone, M Monzini. Nuove modalità terapeutiche nel tromboembolismo venoso: maggiore compliance, efficacia ed efficienza. Anno VII n. 4, 2003: 11-15
- [56] F Rossetti, L Scalone. Epidemiologia e costi delle metastasi ossee: una revisione della letteratura. Anno VII n. 3, 2003: 13-16
- [57] L Scalone. Dermatite atopica: fenomeno sottovalutato, conseguenze socio-economiche sconosciute in Italia. Anno VII n. 1, 2003: 14-19
- [58] L Scalone, LG Mantovani. Valutazione economica della terapia con lisinopril ad alto verso basso dosaggio nel trattamento dei soggetti con scompenso cardiaco cronico – "Economic evaluation high vs low dosage Lisinopril in patients with chronic heart failure". PharmacoEconomics – Italian Research Articles, 2002; 4: 45-55
- [59] L Scalone. Epilessia: dagli aspetti clinici ed epidemiologici alle conseguenze socio-economiche. Anno VI n. 4, 2002: 23-29
- [60] L Scalone. Le demenze nella società e nel sistema sanitario: quali le conseguenze e quali gli interventi. Anno VI n. 3, 2002: 17-22
- [61] L Scalone. La spesa farmaceutica in Italia: ultime tendenze. Anno VI n. 2, 2002: 21-26
- [62] L Scalone. I disturbi del comportamento alimentare: aspetti epidemiologici, economici e di qualità della vita. Anno VI n. 1, 2002: 14-19
- [63] M. Tinelli, L Scalone. Menopausa e terapia ormonale sostitutiva: qualità di vita e farmacoconomia. Anno V n. 3, 2001
- [64] L Scalone. Il disturbo da attacchi di panico. Year V n. 1, 2001: 16-19